Results 11 to 20 of about 1,993 (117)

Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT

Current Oncology, 2021
Peptide receptor radionuclide therapy (PRRT) is used to treat patients with advanced malignant pheochromocytomas (PCCs) and paragangliomas (PGLs).
Erica S. Tsang, Gayle Funk, Janet Leung, Grace Kalish, Hagen F. Kennecke   +4 more
doaj   +3 more sources

Case Report: PRRT in a patient with Zollinger-Ellison syndrome. The management of gastrointestinal complications [PDF]

Frontiers in Oncology
Zollinger-Ellison Syndrome (ZES) is a rare condition characterized by excessive gastric acid secretion due to gastrin-producing neuroendocrine tumors.
Martina Di Franco, Rexhep Durmo, Maria Liberata Di Paolo, Roberto Giacosa, Elisa Bannò, Valentina Ambrosini, Valentina Ambrosini, Angelina Filice   +7 more
doaj   +2 more sources

First results and experience with PRRT in South Africa

World Journal of Nuclear Medicine, 2018
Neuroendocrine tumors (NETs) are a diverse group of tumors that often present late due to nonspecific symptoms. These tumors frequently express somatostatin receptors (SSRs), which allows for positron emission tomography/computed tomography (PET/CT ...
Mariza Vorster, M Modiselle, C Corbett, I Lawal, John Buscombe, Mike Sathekge   +5 more
doaj   +2 more sources

PReCedeNT trial: Phase III randomized-controlled trial of Lutetium − 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

BMC Cancer
Background Peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE is the standard of care for well-differentiated metastatic or locally advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Ameya D. Puranik, Indraja D. Dev, Sushil Yadav, Venkatesh Rangarajan, Archi Agrawal, Sandip Basu, Vikram A. Chaudhari, Anant Ramaswamy, Vikas Ostwal, Manish S. Bhandare, Shailesh V. Shrikhande, Rahul V. Parghane, Prabhat Bhargava, Munita M. Bal, Subhash Yadav, Shraddha Patkar, Mahesh Goel, Nilendu C. Purandare, Sneha Shah, Sayak Choudhury, Suchismita Ghosh, Manikandan Venkatachalam   +21 more
doaj   +2 more sources

Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors

Pharmaceuticals
Background: α-emitting Peptide Receptor Radionuclide Therapy (α-PRRT) is emerging as a promising new generation of PRRT for neuroendocrine tumors (NETs), providing enhanced tumor cell cytotoxicity and reduced irradiation of adjacent healthy tissues due ...
Hannes Leupe, Merel Cauwenbergh, Frederik Cleeren, Jeroen Dekervel, Chris Verslype, Christophe M. Deroose   +5 more
doaj   +2 more sources

PRRT. identikit of the perfect patient [PDF]

, 2020
Peptide receptor radionuclide therapy (PRRT) has been strengthened since the publication of NETTER-1. Nevertheless, the correct positioning in the therapeutic algorithm is debated, and no optimal sequence has yet been standardized.
Dotto A., Di Dato C., Modica R., Colao A., Faggiano A., Albertelli M., Malandrino P., Versari A., Ferone D.   +8 more
core   +1 more source

Evidence base for the use of PRRT [PDF]

, 2020
The development of peptide receptor radionuclide therapy (PRRT) in disseminated neuroendocrine tumors (NETs) has been a long and protracted process. The idea was born within nuclear medicine academia but its translation to clinical practice has been ...
Buscombe, John Richard
core   +1 more source

New Insights in PRRT: Lessons From 2021

, 2022
: Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs has been used for over two decades for the treatment of well-differentiated neuroendocrine tumors (NETs), and the publication of the NETTER-1 trials has further ...
Puliani, Giulia, Appetecchia, Marialuisa, Chiefari, Alfonsina, Lauretta, Rosa, Bianchini, Marta, Mormando, Marilda   +5 more
core   +1 more source

Current Status and Trends in Peptide Receptor Radionuclide Therapy in the Past 20 Years (2000–2019): A Bibliometric Study

Frontiers in Pharmacology, 2021
Background: Peptide receptor radionuclide therapy (PRRT) is an emerging therapeutic option for the treatment of neuroendocrine tumors (NETs), and the number of publications in this field has been increasing in recent years.
Xiaojing Lu, Cuncun Lu, Cuncun Lu, Yongjie Yang, Xiangfen Shi, Haibo Wang, Nan Yang, Kehu Yang, Xiaojian Zhang   +8 more
doaj   +1 more source

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Frontiers in Medicine, 2022
Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding clinical applications. By chelating a radiometal to a somatostatin receptor (SSTR)
Mengqi Shi, Mengqi Shi, Vivianne Jakobsson, Vivianne Jakobsson, Lukas Greifenstein, Pek-Lan Khong, Pek-Lan Khong, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Richard P. Baum, Jingjing Zhang, Jingjing Zhang, Jingjing Zhang   +15 more
doaj   +1 more source